Complement System

Related Products

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Complement System Related Products (208)
Recombinant Proteins (113)
Antibodies (7)

By Effects:	Inhibitors (129) Agonists (13) Controls (2) Ligands (3) Antagonists (21) Activators (7) Modulator (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990753

Omoprubart	Inhibitor
Omoprubart is an anti-C5 complement recombinant humanized monoclonal antibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).

HY-P991962

Anti-CD55 Antibody	Inhibitor
Anti-CD55 Antibody is an anti-CD55 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-50874

BCX 1470	Inhibitor
BCX 1470 inhibits the esterolytic activity of factor D (IC₅₀=96 nM) and C1s (IC₅₀=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.

HY-P990378

Anti-Complement Factor P/Properdin Antibody	Inhibitor	98.04%
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-B0579S5

Cyclosporin A-d₁₂	Inhibitor
Cyclosporin A-d₁₂ (Cyclosporine A-d₁₂) is deuterium labeled Cyclosporin A. Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC₅₀ of 5 nM. Cyclosporin A also inhibits CD11a/CD18 adhesion.

HY-14648S2

Dexamethasone-d₄	Inhibitor	98.93%
Dexamethasone-d₄ is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.

HY-148370C

Sefaxersen sodium scrambled negative control	Inhibitor
Sefaxersen sodium scrambled negative control is the sequence scrambled negative control of Sefaxersen sodium.

HY-138281

Complement factor D-IN-2	Inhibitor	99.33%
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.

HY-145720C

Cemdisiran sodium scrambled negative control
Cemdisiran sodium scrambled negative control is the sequence scrambled negative control of Cemdisiran sodium.

HY-127105B

Iptacopan TFA	Inhibitor
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).

HY-148370

Sefaxersen	Inhibitor	99.46%
Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research.

HY-177611

Agazisiran	Inhibitor
Agazisiran, a siRNA,is a complement factor B synthesis reducer.

HY-P10274

CM05	Inhibitor
CM05 is a bromo-fatty acid. CM05 can be used to modify ornithodoros moubata complement inhibitor (OmCI) and extend the half-life of OmCI.

HY-P1345C

[DArg10, Aib20] TLQP-21	Antagonist
[DArg10, Aib20] TLQP-21, TLQP-21 (HY-P1345) analogue, is a C3aRpartial agonist, C3aR functional antagonist (EC₅₀: 854 nM for β-arrestin recruitment). [DArg10, Aib20] TLQP-21 shows no significant calcium flux activity. [DArg10, Aib20] TLQP-21 shows no activity in potentiating adrenergic-induced lipolysis. [DArg10, Aib20] TLQP-21 can be used in the research of inflammatory diseases, metabolic disorders, and neurological conditions.

HY-P10994

Eps8 peptide 327	Inhibitor
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models.

HY-P10788

CK3 peptide	Inhibitor
CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.

HY-N10400

Campneoside II	Inhibitor
Campneoside II is a compound isolated from Paulownia tomentosa var. tomentosa wood. Campneoside II exhibits excellent anti-complement activity.

HY-147606

Factor B-IN-4	Inhibitor
Factor B-IN-4 (Example 13 target compound) is a potent complement factor B inhibitor, with an IC₅₀ of 1 μM. Factor B-IN-4 can be used for the research of diseases related to inflammation and immunity.

HY-178284

Factor B-IN-7	Inhibitor
Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases.

HY-163378

C5aR1 antagonist 1	Antagonist
C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC₅₀ values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Complement System

Complement System

Complement System Related Products (208)

Recombinant Proteins (113)

Antibodies (7)

Complement System Related Products (208):